
GLP-1 Drugs Push Restaurants Toward Smaller Portions and Protein-Focused Menus
Rising use of GLP-1 weight‑loss medications is reshaping dining and snacking, with diners eating fewer calories and restaurants trimming portions while boosting protein- and fiber-rich options. Brands are racing to market GLP-1–friendly offerings and messaging, as some analysts warn the drugs could wipe out $30–$55 billion in U.S. food-and-beverage sales by 2030, even as pill versions may hasten adoption and the market shift.













